Feb 12, 2026
MannKind’s INHALE‐1ST trial is testing an inhaled insulin, as a needle‐free option for children with type 1 diabetes with an expected FDA decision by May 29, 2026.
Feb 11, 2026
The company has began production of validation lots for its tubeless insulin pump aimed at “almost‐pumpers,” with plans for an early 2026 commercial debut still on track.
Feb 10, 2026
Early clinical data shows the London startup’s tiny, minimally invasive, sensor matches commercial CGM accuracy.
Feb 9, 2026
Dexcom's G7 Trends tab offers users more diabetes insights, showcasing time in range, sensor usage, and key metrics, with more insights expected in the future.
Feb 6, 2026
Insulet's highly anticipated data platform, Omnipod Discover, is available to healthcare providers and Omnipod users across the Middle East.
Feb 5, 2026
Following a 2025 recall of millions of sensors, the FDA points to gaps in Abbott’s quality verification process, sparking renewed discussion on device reliability.
Feb 4, 2026
The warning letter highlights quality system and reporting concerns, but isn't expected to impact the iLet insulin pump production or distribution.
Feb 3, 2026
The updates expand insulin compatibility, sensor pairings, and hint at broader system flexibility ahead.
Feb 2, 2026
Senseonics plans initial rollout of Eversense 365 to begin in Germany, Italy, Spain, and Sweden.
